Metlife Inc (NYSE:MET) has received an average rating of “Hold” from the thirteen research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $50.91.
MET has been the subject of a number of research analyst reports. Morgan Stanley lifted their target price on Williams-Sonoma from $52.00 to $56.00 and gave the stock an “underweight” rating in a report on Wednesday, July 10th. Citigroup downgraded Barrick Gold to a “neutral” rating in a report on Thursday, May 23rd. Wells Fargo & Co set a $33.00 target price on Matador Resources and gave the stock a “hold” rating in a report on Thursday, July 11th. ValuEngine upgraded Yirendai from a “strong sell” rating to a “sell” rating in a report on Friday, May 3rd. Finally, Barclays set a $34.00 target price on DCP Midstream and gave the stock a “hold” rating in a report on Wednesday, May 22nd.
Institutional investors have recently made changes to their positions in the business. Jackson Grant Investment Advisers Inc. grew its stake in Metlife by 4,407.7% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 586 shares of the financial services provider’s stock valued at $25,000 after acquiring an additional 573 shares during the period. Osborn Williams & Donohoe LLC acquired a new stake in Metlife in the first quarter valued at approximately $26,000. Meridian Wealth Management LLC acquired a new stake in Metlife in the first quarter valued at approximately $26,000. Advisory Alpha LLC acquired a new stake in Metlife in the first quarter valued at approximately $27,000. Finally, Semmax Financial Advisors Inc. grew its stake in Metlife by 1,223.6% in the first quarter. Semmax Financial Advisors Inc. now owns 728 shares of the financial services provider’s stock valued at $31,000 after acquiring an additional 673 shares during the period. 75.67% of the stock is owned by hedge funds and other institutional investors.
Metlife (NYSE:MET) last issued its earnings results on Wednesday, May 1st. The financial services provider reported $1.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.18. The business had revenue of $15.45 billion during the quarter, compared to the consensus estimate of $15.95 billion. Metlife had a return on equity of 10.20% and a net margin of 7.56%. The firm’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.36 earnings per share. Research analysts anticipate that Metlife will post 5.59 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Tuesday, August 6th will be paid a $0.44 dividend. The ex-dividend date of this dividend is Monday, August 5th. This represents a $1.76 dividend on an annualized basis and a yield of 3.54%. Metlife’s dividend payout ratio (DPR) is presently 32.65%.
Metlife Company Profile
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.